Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds of Formula (II-II): and compositions thereof, useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Abstract: Provided, in part, are compounds of Formula I. pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-a]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

Abstract: The present invention is directed to 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trofluoroethoxy)pyridine-3-yl)-[1,2,4]triazolo[4,3-?]pyridine, or a pharmaceutically acceptable salt thereof, or a composition thereof, which is useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

Abstract: A guiding sheath has a braided layer for improved deflection characteristics and ring electrodes for electrical sensing, mapping and visualization, wherein lead wires for the ring electrodes are passed through lumened tubing position under the braided layer in a proximal portion of the guiding sheath shaft and above the braided layer in a distal portion of the guiding sheath shaft. Moreover, the hemostatic valve includes an improved friction ring with air vents to reduce the risk of air being introduced into the valve.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

Abstract: An onboard oxygen generation system for an aircraft is operatively connected to an oxygen tank of an oxygen supply system for the aircraft. The oxygen generation system includes an oxygen generator, a water source connected to the oxygen generator, and a power source connected to the oxygen generator. Oxygen produced by the oxygen generator from the water is supplied to the oxygen tank. Hydrogen gas produced by the oxygen generator can be combined with air to form water vapor and either discharged overboard the aircraft through a discharge vent or used to supply water to the water source.

Abstract: Battery systems, methods of in-situ grid-scale battery construction, and in-situ battery regeneration methods are disclosed. The battery system features controllable capacity regeneration for grid-scale energy storage. The battery system includes a battery comprising a plurality of cells. Each cell includes a cathode comprising cathode electrode materials disposed on a first current collector, an anode comprising anode electrode materials disposed on a second current collector, a separator or spacer disposed between the cathode and the anode an electrolyte to fill the battery in the spaces between electrodes. The battery system includes a battery system controller, wherein the battery system controller is configured to selectively charge and discharge the battery at a normal cutoff voltage and wherein the battery system controller is further configured to selectively charge and discharge the battery at a capacity regeneration voltage as part of a healing reaction to generate active electrode materials.

Abstract: An image processing method for harmonizing images acquired by a first camera and a second camera connected to a vehicle and arranged in such a way as their fields of view cover a same road space at different times as the vehicle travels along a travel direction is disclosed. The method includes: acquiring by a selected camera, a first image at a first time; selecting a first region of interest bounding a road portion from the first image; sampling the first region of interest; acquiring by the other camera, a second image in such a way that the road portion is included in a second region of interest; sampling the second region of interest; and determining one or more correction parameters for harmonizing images acquired by the first and second cameras, based on a comparison between the image content of the first and second regions of interest.

Abstract: An onboard oxygen system for aircraft includes an oxygen source, a regulator connected to the oxygen source, and an oxygen mask connected to the regulator. The oxygen source is stored in a cavity in a passenger seat armrest. The oxygen mask is stored in a mask storage compartment attached to the armrest. The oxygen mask is deployed for use through an opening in the mask storage compartment.

Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Abstract: A new and distinct cultivar of Gardenia plant named ‘ST-07-20’ is disclosed, characterized by fragrant, double white flowers, abundant large flowers in spring with reblooming to fall, lustrous, dark green foliage, columnar growth habit, cold hardy to USDA Hardiness Zone 7. The new cultivar is a Gardenia, suitable for ornamental garden purposes.

Abstract: A new and distinct cultivar of Hydrangea plant named ‘CE-01-20’ is disclosed, characterized by bright yellow foliage in the spring, turning to yellow-green in the summer, pink mophead inflorescence in non-aluminum based media and blue inflorescence in aluminum based media, and compact, rounded to spreading growth habit. The new variety is a Hydrangea, typically produced as an outdoor ornamental plant.